Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Fumoleau

Showing results (61-70 of 152) with videos related to

Pageof 16
Sort By:
European Journal of Cancer (Oxford, England : 1990)|June 5, 2004
RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development GroupC J A Punt, M J A de Jonge, S Monfardini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 4, 2015
Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer-results of a first-in-man dose-escalation study with a fixed-dose extension phaseN Isambert, J-P Delord, J-C Soria, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2002
Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administrationCh Dittrich, G Greim, M Borner, et al.
European Journal of Cancer|February 1, 1981
Use of serial carcinoembryonic antigen assays in detecting relapses in breast cancer involving high risk of metastasisJ F Chatal, F Chupin, G Ricolleau, et al.
European Journal of Cancer Care|October 28, 2015
HER2-positivity rates in breast cancer: no variation over time when clinicopathological features and testing are stableF Beltjens, A Bertaut, S Pigeonnat, et al.
European Journal of Cancer (Oxford, England : 1990)|February 5, 2003
Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancerC Dittrich, B Coudert, L Paz-Ares, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Phase II trial of pirarubicin in epidermoid carcinoma of the head and neckP Cappelaere, N Guiochet, J Chauvergne, et al.
European Journal of Cancer (Oxford, England : 1990)|August 31, 2001
UFT and leucovorin in first-line chemotherapy for patients with metastatic gastric cancer. An Early Clinical Studies Group (ECSG)/European Organization for Research Treatment of Cancer (EORTC) phase II trialA Ravaud, M Borner, J H Schellens, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1994
Taxol (paclitaxel) safety in patients with platinum pretreated ovarian carcinoma: an interim analysis of a phase II multicenter studyJ P Guastalla, C Lhommé, J Dauplat, et al.
British Journal of Cancer|September 17, 2009
Gene expression profile and response to trastuzumab-docetaxel-based treatment in breast carcinomaF Végran, R Boidot, B Coudert, et al.
Pageof 16

Showing results (61-70 of 152) with videos related to

Sort By:
Pageof 16
European Journal of Cancer (Oxford, England : 1990)|June 5, 2004
RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development GroupC J A Punt, M J A de Jonge, S Monfardini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 4, 2015
Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer-results of a first-in-man dose-escalation study with a fixed-dose extension phaseN Isambert, J-P Delord, J-C Soria, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2002
Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administrationCh Dittrich, G Greim, M Borner, et al.
European Journal of Cancer|February 1, 1981
Use of serial carcinoembryonic antigen assays in detecting relapses in breast cancer involving high risk of metastasisJ F Chatal, F Chupin, G Ricolleau, et al.
European Journal of Cancer Care|October 28, 2015
HER2-positivity rates in breast cancer: no variation over time when clinicopathological features and testing are stableF Beltjens, A Bertaut, S Pigeonnat, et al.
European Journal of Cancer (Oxford, England : 1990)|February 5, 2003
Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancerC Dittrich, B Coudert, L Paz-Ares, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Phase II trial of pirarubicin in epidermoid carcinoma of the head and neckP Cappelaere, N Guiochet, J Chauvergne, et al.
European Journal of Cancer (Oxford, England : 1990)|August 31, 2001
UFT and leucovorin in first-line chemotherapy for patients with metastatic gastric cancer. An Early Clinical Studies Group (ECSG)/European Organization for Research Treatment of Cancer (EORTC) phase II trialA Ravaud, M Borner, J H Schellens, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1994
Taxol (paclitaxel) safety in patients with platinum pretreated ovarian carcinoma: an interim analysis of a phase II multicenter studyJ P Guastalla, C Lhommé, J Dauplat, et al.
British Journal of Cancer|September 17, 2009
Gene expression profile and response to trastuzumab-docetaxel-based treatment in breast carcinomaF Végran, R Boidot, B Coudert, et al.
Pageof 16